Last month, more than a dozen countries, including Germany, suspended the use of vaccines
A senior official of the European Medicines Agency said that there is a causal relationship between AstraZeneca’s coronavirus vaccine and rare blood clot cases, but added that it is not clear whether the link between the two and whether the benefits of vaccination exceed The risk of contracting the new coronavirus pneumonia (COVID-19): COVID-19: COVID-19.
In an interview with the newspaper Il Messaggero on Tuesday, Marco Cavaleri, head of the Amsterdam-based agency’s health threats and vaccine strategy department, said that the European Union’s drug regulators are preparing for this week. Make a clearer statement.
Cavalieri said that based on the evidence so far, there is an obvious link between the AstraZeneca vaccine and blood clots reported worldwide. This is a rare case because only a few of the tens of millions of vaccines injected This happened. application.
Last month, more than a dozen countries, including Germany, suspended the use of the AstraZeneca vaccine after reporting blood clot problems. European institutions stated that the benefits of this vaccine outweigh the risks of not giving people the vaccine against COVID-19. Most vaccines have resumed vaccination, but there are age restrictions. At that time, the agency recommended updating the vaccine manual to inform doctors and patients about rare cases of blood clots.
Cavalieri said: “It is increasingly difficult to tell the causal relationship between the AstraZeneca vaccine and the very few blood clots associated with low platelets,” Cavalieri said.
He said that he appreciates the need to make clear vaccine safety recommendations for certain age groups in Europe, but he said that he does not think the agency can provide such recommendations now.
“Of course, the information about the product will be updated, and it will be pointed out that these adverse events are related to the vaccine. He said this will be announced very clearly.